In patients with both T2D and chronic HCV infection, the use of dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors), a class of oral antidiabetic drugs, was associated with a lower risk of HCC (43). Here, DPP4 is linked to hepatocellular carcinoma.